Skip to content

Testosterone Gel in Poor Responders Undergoing IVF

Effectiveness of Testosterone Gel Pretreatment in Poor Responders Undergoing IVF Treatment: a Randomized Controlled Trial

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02549690
Enrollment
0
Registered
2015-09-15
Start date
2015-09-30
Completion date
2016-08-31
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

IVF, Testosterone gel, DHEA, poor responder.

Brief summary

The main purpose of this study is to compare the number of oocytes retrieved after using transdermal testosterone gel 10 mg per day or Dehydroepiandrosterone (DHEA) 75mg per day for 6-8 weeks as pre-treatment for poor ovarian responders undergoing in-vitro fertilization (IVF).

Detailed description

A randomized controlled multiple centers study. The study is designed as a superiority trial. The sample size for this trial of 120 subjects in both groups, based upon the primary endpoint of the number of oocytes retrieved. IVF patients who have failed to conceive and had poor ovarian response (oocytes retrieved ≤ 3) in the last stimulated cycle though using the maximal dose, which is ≥ 300 IU Follicle-stimulating hormone (FSH) or human menopausal gonadotropin (hMG). Patients will be randomized to use DHEA or testosterone gel as pretreatment. Randomization will be performed using sealed envelopes developed via a computer generated list with blocks of four. Doctors will be blinded to the randomization, but not patients and nurses. * Study group 1 use 10 mg transdermal testosterone gel per day. * Study group 2 use 75mg DHEA per day. Serum testosterone are measured before treatment. Duration of androgen supplement is 6-8 weeks. After completing the pretreatment, patients are asked to come back when they have menses to begin IVF treatment. Serum testosterone is measured again after the pretreatment in both groups. Patients will be interviewed for side effects and compliance of treatment. After treatment, patients in both group undergo IVF treatment. IVF treatment will then be performed for all patients, according to the current hospital treatment protocols. Patients will be followed up until 7th week of gestation, if they have positive pregnancy test after embryo transfer. Data Analysis and Statistics: The investigators use Statistical Package for the Social Sciences (SPSS) software 20th version to analyze data. The primary end-point mean of number of retrieved oocytes will be compared between two groups using the Student's t test. The secondary end-points will also be compared between the 2 groups using either the Student's t test or chi-square test.

Interventions

DRUGTestosterone gel

Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.

DRUGDHEA

Take DHEA 25mg tablet orally, three times per day. Continue the treatment for 6-8 weeks, until next IVF treatment.

Sponsors

Mỹ Đức Hospital
CollaboratorOTHER
Vietnam National University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 42 Years
Healthy volunteers
No

Inclusion criteria

To be eligible for enrolment into this trial, each female subject must fulfill all of the following criteria at the start of enrolment, unless specified otherwise: * Had one or two previous failure IVF cycle, using GnRH antagonist protocol (≥ 300 IU FSH/hMG per day) and the number of retrieved oocytes are ≤ 3; * Antral follicle counts (AFC) \< 6 or Anti-Mullerian Hormone (AMH) \< 1.26 ng/ml

Exclusion criteria

To be eligible for enrolment in this study each subject must not meet any of the following criteria: * Oocyte donation cycle * Patients have thyroid disease * Patients have liver or kidney dysfunction * Patients have abnormal puberty or genital development. * Patients have previous surgery on ovaries

Design outcomes

Primary

MeasureTime frameDescription
Number of oocytes30 minutes after oocyte retrieval completedNumber of oocytes retrieved Number of oocytes retrieved

Secondary

MeasureTime frameDescription
Clinical pregnancy7 weeks after embryo transferClinical pregnancy is defined by the image gestational sac under ultrasonography

Countries

Vietnam

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026